Stockscreener 앱 받기
86.97
0.49%
0.42
시간 외 거래:
86.92
-0.05
-0.06%
전일 마감가:
$86.55
열려 있는:
$87.275
하루 거래량:
1.91M
Relative Volume:
0.95
시가총액:
$12.25B
수익:
$622.01M
순이익/손실:
$-271.86M
주가수익비율:
-40.48
EPS:
-2.1484
순현금흐름:
$-45.87M
1주 성능:
+6.70%
1개월 성능:
+18.99%
6개월 성능:
+32.39%
1년 성능:
+416.45%
1일 변동 폭
$83.79
$87.57
1주일 범위
$78.81
$87.83
52주 변동 폭
$14.30
$87.83
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
86.97 | 12.19B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Pharmaceuticals stock hits 52-week high at 84.65 USD - Investing.com
Price to book forward of Arrowhead Pharmaceuticals, Inc. – NASDAQ:ARWR - TradingView
Arrowhead Pharmaceuticals, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh - TradingView
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Arrowhead Pharma stock rating at buy - Investing.com
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $110 - Moomoo
ARWR Maintained by Chardan Capital -- Price Target Steady at $90 - GuruFocus
Arrowhead Pharmaceuticals Price Target Maintained With a $90.00/Share by Chardan Capital - Moomoo
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development ProgramsSlideshow (NASDAQ:ARWR) 2026-06-30 - Seeking Alpha
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Arrowhead Pharmaceuticals eyes Q3 SHASTA data as REDEMPLO approvals build momentum - MSN
Arrowhead Pharmaceuticals, Inc.(NasdaqGS: ARWR) dropped from Russell 2000 Index - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Midcap Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals Inc R&D Webinar (Virtual) Transcript - GuruFocus
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 1000 Growth Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from Russell 2000 Dynamic Index - marketscreener.com
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell 3000E Value Benchmark - marketscreener.com
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ARWR) - TradingView
Arrowhead Pharmaceuticals, Inc. Actuals & Estimates (SWB:HDP1) - TradingView
HDP1 Forecast — Price Target — Prediction for 2027 - TradingView
A2AGYB Forecast — Price Target — Prediction for 2027 - TradingView
ARWR Forecast — Price Target — Prediction for 2027 - TradingView
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree - AOL.com
Liquidity Mapping Around (ARWR) Price Events - Stock Traders Daily
Arrowhead Pharmaceuticals (ARWR) Leads Healthcare Stocks with St - GuruFocus
Arrowhead Pharmaceuticals gets EC approval for REDEMPLO in FCS - grafa.com
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals (ARWR) Receives EU Approval for REDEMP - GuruFocus
EU approves Arrowhead's REDEMPLO for rare fat disorder FCS - Stock Titan
The Insider Report: Stocks Celebrate Peace and a New Fed Chapter - Benzinga
Are Arrowhead Pharmaceuticals’ (ARWR) Board Moves and RNAi Webinars Quietly Reframing Its Risk Narrative? - Sahm
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update - Sahm
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars - Business Wire
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30 By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals Inc (ARWR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arrowhead Pharmaceuticals Inc - TradingKey
Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR) - Stock Titan
Arrowhead Pharmaceuticals Rises as Recent Clinical Updates and EU Catalyst Keep Focus on Plozasiran - Quiver Quantitative
Arrowhead Pharmaceuticals stock hits 52-week high at $82.30 - Investing.com
ARWR Maintained by Leerink Partners -- Price Target Raised to $7 - GuruFocus
Arrowhead Pharmaceuticals (ARWR) director files Form 3 showing zero share ownership - Stock Titan
Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant - Stock Titan
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
2.48%
자본화:
|
볼륨(24시간):